Epcoritamab is an FDA-approved bispecific antibody for relapsed/refractory (R/R) large B-cell lymphomas (LBCLs). Real-world outcomes and safety data remain limited. We analyzed 157 adult patients with R/R aggressive BCLs who received epcoritamab outside of a clinical trial between 2023-2025 at 9 centers in the Collaborative US Bispecifics Consortium (CUBIC). The best overall response rate (ORR) was 49.6% and best complete response rate (CRR) was 31.9%. With a median follow up of 15.8 months, the 1-year progression free survival (PFS) and overall survival (OS) rates among all patients were 29% (95% CI: 22-37%) and 38% (95% CI: 31-47%), respectively. Inferior overall response rates and complete response rates were observed in patients with high IPI, elevated LDH, 2 extranodal (EN) sites and disease refractory to prior LOT (pLOT). In multivariable analysis, ECOG PS 2, elevated LDH, refractory disease to pLOT and clinical trial ineligibility were associated with inferior PFS and OS. Among all patients, 33% had any grade cytokine release syndrome (CRS) (grade 3 of 4.6%), while immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 12% ( G3 0.6%) of patients. ICU admission occurred in 17% of patients. Compared to pivotal trials and other real-world studies, we observed inferior response rates and survival outcomes as well as a higher rates of G3+ CRS, any grade ICANS, and ICU admission.
Bock et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: